New imaging agent aims to spot hidden immune cells in tumors
NCT ID NCT04168528
First seen Jun 04, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumor-associated macrophages on PET/CT scans in people with breast cancer or melanoma. The study planned to enroll 13 adults with solid tumors, but it was terminated early. The goal was to assess safety, how the agent spreads in the body, and whether it could help visualize tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uz Brussel
Brussels, Brussels Capital, 1090, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68GaNOTA-Anti-MMR-VHH2 (a radioactive imaging agent injected before a PET/CT scan)
What this could lead to
If successful, this could provide a new way to see certain immune cells around tumors, potentially helping doctors better understand and monitor cancers.
What could go wrong
This was a very early, small trial that was terminated, so results are limited. The imaging agent may not reliably highlight tumors or may cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.